Brian Overstreet

Brian Overstreet

Recent Posts

March 3, 2017

Make Hair Great Again - The Real Reason for FDA Reform

A personal note:  About a month ago, we published a blog post titled Drug Safety Progressives.  While 99.9% of the readers understood that this wasn’t a political statement, we did get hit with some great trolling that accused us of, among other things, pushing “Alt-Left Propaganda on a Left Wing Socialist website.”  How or why someone reached that conclusion is beyond me.  Regardless, I’m dedicating today’s blog post to those 0.1% of our readers who troll for an internet fight.  I’m confident that the rest of you will enjoy it too.

We know that with the fake news circulating these days, you may have missed the most important breaking story concerning President Trump in February.  That’s right, he’s taking something to maintain that famous hair – Propecia.

Read More
February 24, 2017

A Big Data Stumble in Healthcare

This week marked the annual HIMSS Conference.  HIMSS, Healthcare Information and Management Systems Society, is the big annual gathering of IT firms trying to market their wares into healthcare systems, pharmaceutical companies, and health insurers.

While usually a time for big partnerships, acquisitions, deployments, and new client wins, this year’s HIMSS kicked off in a rather inglorious manner.  On Sunday news broke that world-renowned cancer center MD Anderson had discontinued their partnership with IBM Watson.  After a string of big wins by the Watson team, this appeared to be the first – and certainly the largest – setback.

Read More
January 26, 2017

Advera Health Partners with APCER Life Sciences to Connect Drug Safety to Health Outcomes

We were very excited this Monday to announce a new partnership with APCER Life Sciences, a global provider of safety, medical, regulatory, and technology services to the pharmaceutical industry.  Working with the dedicated professionals at APCER will enable us to expand our reach into the safety and pharmacovigilance departments at pharmaceutical companies globally. 

Read More
January 12, 2017

Will 2017 Be The Year of Drug Safety?

On this past Sunday’s 60 Minutes, astronomer Mike Brown made a bold prediction – that within three years the scientific community would identity a new, large 9th planet located in the outermost area of our solar system.  Even more astonishing was how certain he was about that prediction, “I would say at this point, I am certain….that’s a rare thing to say – for a prediction for a scientist.  And I’m willing to say it.”  Mike Brown has some credibility in this area, as he’s the guy who figured out that Pluto wasn’t a planet after all.  Maybe it’s his own guilt over breaking every school-kid’s heart that’s driving his prediction, but both his prediction and his certainty really fascinated me.  If you haven’t watched the report, I’d urge you to do so (link is here).

Read More
December 16, 2016

Looking Ahead - Drug Safety in 2017

As 2016 winds down, am I the only one who feels exhausted? 

Between pharma-bro inspired drug pricing madness, a political season that felt like a Bravo reality TV show, and Leicester City robbing my beloved Tottenham Hotspur of their first shot at a Premiere League championship in a very long time, I think John Oliver summed up this year best in this video.

Read More
November 11, 2016

When Things Go Right in Healthcare


In these blog posts we’re often guilty of highlighting the worst in healthcare (see, for example, here, here, and here).  That attitude shouldn’t be totally surprising when we started Advera Health Analytics with a mission to correct a glaring problem in the healthcare system – the lack of transparent drug safety and efficacy data.   That said, it seems only fair to give credit where it’s due when things go exactly right.  This is one of those stories.

Read More
October 20, 2016

Why Does Adverse Event Reporting to FAERS Continue to Accelerate?

faers_growth.pngSeventy two hours after 2016 Q2 FDA Adverse Event Reporting System (FAERS) data were publicly released by FDA, our RxFilter® process had it standardized and loaded into the Evidex platform.  Based on the volume of data in Q2, it looks like we’re well on the way to yet another record year of adverse events reported into FAERS. 

Here is a chart of new case reports (including our estimate for full year 2016).  Note that these numbers are based on a clean dataset; de-duplicated, primary suspect cases only).

Read More
September 22, 2016

HHS Says they are Finally Going to Enforce Clinical Trial Reporting. Will Anything Really Change?


Last December, Stat News wrote a scathing report on the chronic under reporting of clinical trial results.  We followed that up in July with our own blog post, highlighting specific under reporting rates we’ve found in just a handful of indications.

Read More
September 1, 2016

Drug Safety Snail Mail. Really?


Last week the U.S. Surgeon General Vivek Murthy sent a letter to every doctor in the U.S. to warn them of the dangers of opioid addiction.  While certainly well intentioned, I have to ask - in this age of technology, is this the best we can do?  Why not fax or, even better, send a Western Union cable?

Read More
August 19, 2016

The Drug Pricing Battle Wages On


The battle over drug pricing took an interesting turn here in California this week.  On the heels of such negative publicity about high priced prescription drugs, giant price spikes for certain medications, and general bad behavior among certain high profile biotech executives, it’s not surprising that regulators and government bodies are starting to weigh in on ways to regulate or control drug price increases.

Read More